encourag sign late april may
management keep bar anyway
reiter outperform target price
management see encourag sign late april may expect sequenti improv
thru management cite exampl improv trend april may us
geographi corrobor recent comment compani elect procedur
exposur set stage gradual improv growth throughout howev
given remain earli recoveri process across countri globe pin
expect investor view rel low growth margin target
slightli y/i gm sequenti off-set encourag
expect total revis sale estim lower higher
essenti unchang full year suspect mgmt initi
expect may prove conserv reiter outperform rate target
organ growth ep right in-lin expect
margin expect step sequenti consist compani
coverag univers management provid guidanc come year direct
commentari provid indic gm could declin sequenti
addit management expect op ex increas mil sequenti combin
reduct gm put project op mgn prior
estim model sequenti improv margin growth throughout
steep drop expect sale margin caught investor guard
believ creat potenti upsid elect volum continu improv
new product launch impact regulatori approv continu
move forward launch affect current environ includ percept db
interstim micro cobalt chrome icds/crt-d diamond temp rf ablat cathet
eu dtm therapi micra av regulatori front management encourag
seen meaning delay current pend regulatori approv includ approv
interstim micro percept reveal linq minim eu approv minim
chang model weve rais sale estim mil lower
ep estim
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag may
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
medtron plc global manufactur provid medic devic
equip area cardiac rhythm manag vascular
intervent structur valvular diseas spinal disord
neuromodul surgic equip diabet
one-year valuat scenario base
ev/ebitda ebitda estim bil
one-year valuat grey scenario base
ev/ebitda grey ebitda estim bil
 close
mariu zoican univers toronto rotman school manag may
addit detail takeaway
 heart failur sale mil mil decreas organ arrhythmia
manag sale icd pacemak declin
af solut given higher impact
implant diagnost april deferr procedur volum slow
dramat leadless pacemak grew hsd low-twenti
februari march growth due continu adopt micra heart failur
declin reflect declin crt-d crt-p mid-
lvad
coronari structur heart sale mil mil decreas organ
tavr sale declin management note strong implant trend
estim compani held sequenti ww procedur share cardiac surgeri sale
high-teen partial off-set strong ecmo demand coronari driven
reduct procedur volum
aortic peripher venou sale mil mil decreas organ
taa aaa declin venou reflect
deferr natur procedur ww dcb sale declin
surgic innov sale bil mil decreas organ
advanc surgic sale april due deferr procedur
halt also saw declin advanc advanc stapl
gener surgic due procedur volum reduct
respiratori gastrointestin renal sale mil mil increas
organ respiratori sale grew seek meet ww ventil need
track increas ventil product end june recal march
announc doubl capac manufactur suppli ventil
manag infect patient monitor sale flat deferr
procedur mix off-set region spike demand nellcor puls oximetri
microstream capnographi product capnographi strong dd growth
demand renal solut hsd due strong demand renal access cathet
acute/chron bellco consum context april fda grant market
author carpediem system design extracorpor blood treatment
gi solut sale reflect deferr procedur mix
brain therapi sale mil mil decreas organ neurovascular
sale hsd partial off-set growth ischem stroke therapi product ischem
grew hsd driven sale riptid aspir system react aspir cathet
hemorrhag sale declin mid-teen driven deferr hemorrhag stroke case
unruptur aneurysm immedi risk ruptur neurosurgeri sale declin
due hospit delay capit equip purchas saw rel strength mida
power surgic instrument stealthstat sale db sale declin
result procedur deferr reduct normal year-end custom bulk purchas
mariu zoican univers toronto rotman school manag
spine sale mil mil decreas organ spine combin
enabl technolog spine-rel enabl technolog revenu reflect neurosurgeri
declin reflect delay capit equip evalu purchas spine
declin driven procedur deferr
specialti therapi sale mil mil decreas organ ent
reflect pullback ent procedur pelvic health declin due
deferr snm procedur market share increas follow european
launch interstim micro
pain therapi sale mil mil decreas organ intervent
compani saw compar fewer defer procedur pain target drug
deliveri declin due procedur deferr
ou sale account approxim half total sale vs last quarter
reflect impact revenu declin high-teen primarili due
delay new patient start close physician offic competit challeng guardian
connect grew ldd despit headwind cgm growth driven ww strength
integr stand alon cgm within stand alon cgm mdt guardian connect
smart cgm system continu momentum growth despit pandem
integr cgm saw strong global growth driven increas cgm penetr new
patient acquisit partial off-set impact insulin pump pandem
result close physician offic delay new patient start management see
continu competit pressur
mariu zoican univers toronto rotman school manag may
guid withheld comment point
management provid guidanc given uncertainti caus pandem
provid help qualit commentari management assum second wave
adequ contain believ seen worst procedur declin
see encourag sign earlier-than-anticip recoveri sever geographi ww
geograph china management note reduct weekli revenu declin first
week may believ recoveri alreadi underway part asia
japan india management note compani still experienc sever y/i procedur
declin expect lockdown impact market like australia new
zealand korea continu see recoveri western europ management
start see sequenti revenu improv may seen weekli revenu
across western europ declin prior year vs april
declin period
management expect revenu growth modestli wors total
compani busi compani largest region like experi full
quarter impact compar five six week specif management
expect rtg revenu challeng follow cvg expect
declin total compani mitg diabet also expect declin
well expect better compani averag management expect
better sequenti improv remaind
management expect back normal revenu growth two-year stack basi
 management expect gm point sequenti sg
 coupl hundr million dollar higher oper profit expect improv
throughout year
urgentmoder electivemor electivecardiac vascular group pace aortic coronari cardiac surgeri icds/crt-d tavr/structur heart peripher af solut endoven diagnosticsminim therapi group surgic innov appendectomi bowel obstruct trauma respiratori patient monitor renal surgic innov cabg oncolog surgic innov bariatr hysterectomi hernia girestor therapi group spine trauma neurovascular ischem stroke brain modul neurovascular hemorrhag stroke spine pain therapi pelvic health entdiabet group diabet suppli new insulin pump mariu zoican univers toronto rotman school manag may
 op margin bp estim
sale net cog higher off-set lower sg tax
deliv ep cse gross margin bp y/i
bp estim due increas expens result includ
manufactur facil clean increas ppe bonus factori employe higher
freight obsolesc charg addit experienc neg impact mix
higher demand product carri lower-margin compani also continu experi
year-over-year impact increas china tariff
estimate bpother bpop bpnon-op bpnet chg y/i mariu zoican univers toronto rotman school manag may
estimate var salesy/i chg cc chg org chg salesy/i chg cc chg org chg gastro mariu zoican univers toronto rotman school manag may
chang model
weve rais sale estim mil lower ep estim
sale ep project beyond remain larg unchang
figur chang model
valuat target price base ebitda multipl ebitda
estim bil risk product delay unexpect execut issu failur progress
long-term goal growth margin potenti new litig regulatori qualiti issu
greater expect impact
 peripher gastrointestin mariu zoican univers toronto rotman school manag may
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
